We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Prasugrel Recommended to Treat ACS, Cancer and Clotting Risks Downplayed
Prasugrel Recommended to Treat ACS, Cancer and Clotting Risks Downplayed
February 6, 2009
An FDA advisory committee voted unanimously to recommend approval of Eli Lilly and Daiichi Sankyo’s anti-clotting drug prasugrel to treat acute coronary syndrome (ACS).